Nides Mitchell, Glover Elbert D, Reus Victor I, Christen Arden G, Make Barry J, Billing Clare B, Williams Kathryn E
Los Angeles Clinical Trials, 4116 W. Magnolia Boulevard, Burbank, CA 91505, USA.
Am J Health Behav. 2008 Nov-Dec;32(6):664-75. doi: 10.5555/ajhb.2008.32.6.664.
To evaluate varenicline's efficacy for smoking cessation versus bupropion SR and placebo and to explore whether factors typically predictive of abstinence influence varenicline's efficacy versus placebo, as measured by the week 9-12 continuous abstinence rate (CAR9-12).
Smokers in 2 randomized, placebo-controlled trials received varenicline 1 mg BID (n=696), bupropion SR 150 mg BID (n=671), or placebo (n=685) for 12 weeks. Nontreatment followup lasted 40 weeks.
CAR(9-12) was greater for varenicline (44.0%) versus bupropion SR (29.7%; P<0.0001) and placebo (17.7%; P<0.0001). CAR(9-12) for varenicline versus placebo was not affected by age, gender, or nicotine dependence level.
Varenicline was more efficacious than bupropion SR or placebo. Varenicline's efficacy versus placebo was not influenced by factors predictive of abstinence.
评估伐尼克兰相对于安非他酮缓释片和安慰剂在戒烟方面的疗效，并探讨通常预测戒烟成功的因素是否会影响伐尼克兰相对于安慰剂的疗效，以第9至12周持续戒烟率（CAR9 - 12）来衡量。
在两项随机、安慰剂对照试验中，吸烟者接受12周的伐尼克兰1毫克每日两次（n = 696）、安非他酮缓释片150毫克每日两次（n = 671）或安慰剂（n = 685）治疗。非治疗随访持续40周。
伐尼克兰的CAR(9 - 12)（44.0%）高于安非他酮缓释片（29.7%；P < 0.0001）和安慰剂（17.7%；P < 0.0001）。伐尼克兰相对于安慰剂的CAR(9 - 12)不受年龄、性别或尼古丁依赖水平的影响。
伐尼克兰比安非他酮缓释片或安慰剂更有效。伐尼克兰相对于安慰剂的疗效不受预测戒烟成功因素的影响。
